Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Melanoma 11Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasms 4Sarcoma 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Pancreatic Ductal Adenocarcinoma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1

Interventions

Paclitaxel 4pembrolizumab 2pazopanib 2efatutazone 2Sorafenib 2Radiotherapy, Intensity-Modulated 2trametinib 1tislelizumab 1surufatinib 1spartalizumab 1sapanisertib 1lenvatinib 1fosbretabulin 1dabrafenib 1crolibulin 1combretastatin 1cabozantinib 1atezolizumab 1abemaciclib 1Taxes 1Imatinib Mesylate 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1Carboplatin 1CUDC-907 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Carcinoma, Anaplastic × spartalizumab × Clear all
NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Completed
319 enrolled 41 charts
BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡